Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Currier, M. B. Articles by Kato, M. Search for Related Content PubMed Citation Articles by Currier, M. B. Articles by Kato, M. AIDS/HIV Depression Antidepressants

A Prospective Trial of Sustained-Release Bupropion for Depression in HIV-Seropositive and AIDS Patients

Presented in part at the 154th annual meeting of the American Psychiatric Association, New Orleans, May 5–10, 2001. Received June 24, 2002; accepted July 24, 2002. From the Department of Psychiatry and Behavioral Sciences, Division of Consultation Psychiatry, University of Miami School of Medicine. Address reprint requests to Dr. Currier, Department of Psychiatry (D-79), Division of Consultation Psychiatry, University of Miami/Jackson Memorial Medical Center, 1400 N.W. 10 Ave., Suite 704A, Miami, FL 33136; bcurrier{at}med.miami.edu (e-mail).

To date, the authors know of no prospective studies of sustained-release bupropion in depressed HIV-seropositive patients. The purpose of this study was to evaluate the efficacy and tolerability of sustained-release bupropion in 20 depressed HIV-positive adult outpatients. Twenty outpatients with HIV spectrum illness, a DSM-IV-diagnosed major depressive disorder confirmed with the Structured Clinical Interview for DSM-IV, and Mini-Mental State Examination scores >20 were recruited into a 6-week, open-label, flexible-dose study of sustained-release bupropion (100–300 mg/day). Twelve patients (60%) responded to sustained-release bupropion at a mean dose of 265 mg/day. Five patients (25%) discontinued study participation secondary to adverse events. Preliminary findings suggest that sustained-release bupropion is effective for the treatment of depression in HIV-positive patients, regardless of HIV clinical staging. Furthermore, it appears to be well tolerated in patients with AIDS-related medical conditions.

This article has been cited by other articles:

				M. J. Repetto and J. M. Petitto Psychopharmacology in HIV-Infected Patients Psychosom Med, June 1, 2008; 70(5): 585 - 592. [Abstract] [Full Text] [PDF]

				L. M. Hesse, D. J. Greenblatt, L. L. von Moltke, and M. H. Court Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J. Clin. Pharmacol., May 1, 2006; 46(5): 567 - 576. [Abstract] [Full Text] [PDF]

				M. B. Currier, G. Molina, and M. Kato Citalopram Treatment of Major Depressive Disorder in Hispanic HIV and AIDS Patients: A Prospective Study Psychosomatics, June 1, 2004; 45(3): 210 - 216. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us